Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

Eadb,Ifgc,Ipdgc,RiMod-FTD (Risk),Modifying factors in Fronto-Temporal Dementia,Netherlands Brain Bank,Desgesco

Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

2020

Eadb
Ifgc
Ipdgc
RiMod-FTD (Risk)
Modifying factors in Fronto-Temporal Dementia
Netherlands Brain Bank
Desgesco

The IPDGC (The International Parkinson Disease Genomics Consortium) and EADB (Alzheimer Disease European DNA biobank) are listed correctly as an author to the article, however, they were incorrectly listed more than once.

Keywords:

Missense mutation
Disease
Frontotemporal dementia
Dementia with Lewy bodies
Longevity
Pathology
PLCG2
Biology
Biobank
Bioinformatics
Alzheimer's disease
Genomics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations